David Allmond
Corporate Officer/Principal at POOLBEG PHARMA PLC
Net worth: 38 652 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Luke O'Neill | M | 60 | - | |
| Jeremy Skillington | M | 53 | 3 years | |
| Cathal Friel | M | 59 | 4 years | |
| Brendan Buckley | M | 73 | 1 years | |
| John McEvoy | M | 37 |
Amryt Pharma Holdings Ltd.
 Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
| Ian O'Connell | M | 37 | 3 years | |
| Eddie Gibson | M | 50 | 3 years | |
| Ross Crockett | M | - | 3 years | |
| Salim Hamir | M | - | - | |
| Bruno Speder | M | - | 2 years | |
| David English | M | - | 2 years | |
| Carol Dalton | F | - | 3 years | |
| Laura Maher | F | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Sol Barer | M | 76 | 25 years | |
| Jacqualyn Fouse | M | 62 | 7 years | |
| Jonathan Biller | M | 61 | 8 years | |
| Scott Smith | M | 61 | 10 years | |
| Perry Karsen | M | 69 | 9 years | |
| Graham David Mullis | M | 62 | 7 years | |
| Thomas Daniel | M | 69 | 10 years | |
| Tracy Cunningham | M | - |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
| Michael Friedman | M | 80 | 8 years | |
| Carrie Cox | F | 66 | 10 years | |
| Thomas Perone | M | 59 | 12 years | |
| Sandy Mahatme | M | 59 | 6 years | |
| Brendan Delaney | M | 49 | 6 years | |
| Anthony Culverwell | M | 68 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | 3 years |
| Jay Backstrom | M | 69 | 11 years | |
| Alain Munoz | M | 75 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
| Stephen Joyce | M | - |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
| Patrick E. Flanigan | M | - | - | |
| Rodman L. Drake | M | 80 | 8 years | |
| James J. Loughlin | M | 81 | 12 years | |
| Ernest Mario | M | 85 | 12 years | |
| William Rastetter | M | 76 | 6 years | |
| John W. Jackson | M | 78 | 10 years | |
| Derval O'Carroll | F | 58 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
| Patrick Jordan | M | - |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
| Navin Nauth-Misir | M | - | - | |
| Alexander Reynolds | M | - | 13 years | |
| Jian Ming Mei | M | 58 | 9 years | |
| Terrence Connolly | M | - | 8 years | |
| Deya Corzo | M | 57 | 2 years | |
| Michele Bellandi | M | - |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
| Bryan Close | M | - | - | |
| Michael Pehl | M | 60 | 11 years | |
| Kareem Reda | M | - | - | |
| Nadim Ahmed | M | 56 | 9 years | |
| Gregory Russotti | M | 57 | 13 years | |
| Jordi Casals | M | - |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
| Guillermo Raimondo | M | - | 1 years | |
| Neil S. Belloff | M | 64 | - | |
| Jorge DiMartino | M | 60 | 8 years | |
| Kevin Patrick Lynch | M | 59 | 8 years | |
| Axel Gaston Glasmacher | M | 64 | 12 years | |
| Wai-Yip Lee | M | 51 | 5 years | |
| Emily Minkow | F | 41 | 7 years | |
| Peter Greaney | M | 45 | 12 years | |
| Markus Ziener | M | 58 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | 3 years |
| Julie Eastwood | F | - |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
| Jennifer Creel | F | 53 | 12 years | |
| Daniel Wilson | M | 53 | 8 years | |
| Benjamin Winograd | M | 63 | 13 years | |
| George Hampton | M | 54 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
| Frank T. Cary | M | 103 | 19 years | |
| Donald Stern | M | 78 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
| Catherine B. Elflein | F | 63 | 14 years | |
| Stephen Wills | M | 67 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | 4 years |
| Kristen Hege | M | 60 | 9 years | |
| Alan Colowick | M | 61 | 7 years | |
| Karen Brophy | F | 60 | 6 years | |
| Arthur Hull Hayes | M | 89 | 15 years | |
| Walter L. Robb | M | 95 | 19 years | |
| David Gryska | M | 68 | 4 years | |
| Isaac E. Ciechanover | M | 53 | 6 years | |
| Joseph S. Camardo | M | 69 | 10 years | |
| Dennis Cho | M | 53 | 9 years | |
| Harry Thomas Stratford | M | 54 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | 3 years |
| John D. Soriano | M | 62 | 7 years | |
| Jillian F. Evans | M | - | 1 years | |
| Quang M. Pham | M | 40 | 1 years | |
| Mitchall G. Clark | M | 63 | 1 years | |
| Ye Hua | M | - | 3 years | |
| Jarl Ulf Birger Jungnelius | M | 73 | 7 years | |
| Philippe Martin | M | - | 7 years | |
| Janice M. Smiell | M | - | 4 years | |
| Kieran Rooney | M | - |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
| Fe Batara | F | - | 1 years | |
| Michael N. Needle | M | 64 | 6 years | |
| Rajesh Chopra | M | 63 | 7 years | |
| Maureen T. Cronin | M | 70 | 5 years | |
| Patrick Volkert Vink | M | 60 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
| David R. Webb | M | 79 | 8 years | |
| Jean Bizzari | M | 69 | 7 years | |
| Elizabeth Jobes | F | 57 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
| Neil Desai | M | 59 | 6 years | |
| Edward Dulac | M | 49 | 8 years | |
| George Golumbeski | M | 67 | 9 years | |
| Thomas Bock | M | 60 | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 65 | 65.66% |
| United Kingdom | 30 | 30.30% |
| France | 4 | 4.04% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- David Allmond
- Personal Network
